These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

572 related items for PubMed ID: 2948049

  • 1. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T, Fujiwara H, Mizushima Y, Shearer GM, Hamaoka T.
    J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
    [Abstract] [Full Text] [Related]

  • 2. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
    Takai Y, Kosugi A, Yoshioka T, Tomita S, Fujiwara H, Hamaoka T.
    J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H, Yoshioka T, Shima J, Kosugi A, Itoh K, Hamaoka T.
    J Immunol; 1986 Apr 01; 136(7):2715-9. PubMed ID: 3005417
    [Abstract] [Full Text] [Related]

  • 5. T cell responses induced by the parenteral injection of antigen-modified syngeneic cells. I. Induction, characterization, and regulation of antigen-specific T helper cells involved in delayed-type hypersensitivity responses.
    Miller SD, Butler LD.
    J Immunol; 1983 Jul 01; 131(1):77-85. PubMed ID: 6190929
    [Abstract] [Full Text] [Related]

  • 6. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S, Fujiwara H, Yamane Y, Sano S, Nakajima H, Izumi Y, Arai H, Kawanishi Y, Tsuchida T, Hamaoka T.
    Jpn J Cancer Res; 1986 Feb 01; 77(2):182-9. PubMed ID: 3082830
    [Abstract] [Full Text] [Related]

  • 7. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
    Fujiwara H, Aoki H, Yoshioka T, Tomita S, Ikegami R, Hamaoka T.
    J Immunol; 1984 Jul 01; 133(1):509-14. PubMed ID: 6233375
    [Abstract] [Full Text] [Related]

  • 8. The mechanism of tolerance induction of tumor-specific delayed-type hypersensitivity responses by intravenous inoculation of tumor cells.
    Sato S, Fukuzawa M, Nakajima H, Ogata M, Kosugi A, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1985 Nov 01; 76(11):1099-106. PubMed ID: 2935516
    [Abstract] [Full Text] [Related]

  • 9. T-T cell interaction in the in vitro induction of delayed-type hypersensitivity (DTH) responses: demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of DTH responses.
    Kosugi A, Takai Y, Ogata M, Fujiwara H, Hamaoka T.
    J Leukoc Biol; 1985 May 01; 37(5):629-39. PubMed ID: 3156939
    [Abstract] [Full Text] [Related]

  • 10. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
    Izumi Y, Tsuchida T, Okuno K, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1985 Sep 01; 76(9):863-70. PubMed ID: 3932286
    [Abstract] [Full Text] [Related]

  • 11. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T.
    J Immunol; 1984 Sep 01; 133(3):1671-6. PubMed ID: 6205091
    [Abstract] [Full Text] [Related]

  • 12. The augmentation of tumor-specific immunity by virus help. I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses.
    Fujiwara H, Shimizu Y, Takai Y, Wakamiya N, Ueda S, Kato S, Hamaoka T.
    Eur J Immunol; 1984 Feb 01; 14(2):171-5. PubMed ID: 6199215
    [Abstract] [Full Text] [Related]

  • 13. Genetic control of hapten-reactive helper T-cell responses and its implications for the generation of augmented antitumor cytotoxic responses.
    Mizushima Y, Fujiwara H, Takai Y, Shearer GM, Hamaoka T.
    J Natl Cancer Inst; 1985 Jun 01; 74(6):1269-73. PubMed ID: 3158772
    [Abstract] [Full Text] [Related]

  • 14. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
    Shimizu Y, Hasumi K, Masubuchi K, Okudaira Y.
    Eur J Immunol; 1988 Nov 01; 18(11):1773-8. PubMed ID: 2974424
    [Abstract] [Full Text] [Related]

  • 15. The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells.
    Shimizu Y, Fujiwara H, Ueda S, Wakamiya N, Kato S, Hamaoka T.
    Eur J Immunol; 1984 Sep 01; 14(9):839-43. PubMed ID: 6236991
    [Abstract] [Full Text] [Related]

  • 16. Delayed-type hypersensitivity induced in immunodeficient mice with syngeneic modified self antigens: a suggestive model of autoimmune response.
    Tarcic N, Naor D.
    Eur J Immunol; 1982 Nov 01; 12(11):961-6. PubMed ID: 6983970
    [Abstract] [Full Text] [Related]

  • 17. Effect of helper T cells on prevention of tolerance induction in effector T cells responsible for syngeneic tumor immunity.
    Fujiwara H, Kinouchi T, Tsuchida T, Aoki H, Hamaoka T.
    Gan; 1982 Oct 01; 73(5):766-72. PubMed ID: 6219908
    [Abstract] [Full Text] [Related]

  • 18. T-cell responses induced by the parenteral injection of antigen-modified syngeneic cells. II. Mechanisms, specificity, and cellular analysis of 2,4,6-trinitrophenol (TNP)-specific cytolytic response priming by intravenous versus subcutaneous injection with TNP-modified syngeneic cells.
    Miller SD, Butler LD, Cleveland RP, Moorhead JW, Claman HN, Chiller JC.
    Cell Immunol; 1983 Dec 01; 82(2):378-93. PubMed ID: 6197193
    [Abstract] [Full Text] [Related]

  • 19. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
    Fujiwara H, Takai Y, Sakamoto K, Hamaoka T.
    J Immunol; 1985 Sep 01; 135(3):2187-91. PubMed ID: 3874911
    [Abstract] [Full Text] [Related]

  • 20. Analysis of Ir gene control of cytotoxic response to hapten-modified self: helper T cells specific for a sulfhydryl hapten can substitute for an anti-TNP-H-2b self helper cell defect.
    Fujiwara H, Levy RB, Shearer GM.
    J Immunol; 1981 Sep 01; 127(3):940-5. PubMed ID: 6167635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.